ArticleFrontiers in medicine2025
Intensive glycemic control and kidney disease risk: insights on hierarchical composite endpoint from a randomized clinical trial.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Clinical trials of intensive glycemic control in patients with type 2 diabetes mellitus (T2DM) and high cardiovascular risk have reported inconsistent findings regarding chronic kidney disease (CKD) outcomes, partly due to heterogeneity in event definitions and reliance on conventional time-to-first-event analysis. This study aimed to evaluate the renal effects of intensive glycemic control using a hierarchical composite endpoint (HCE) ranked by clinical severity and analyzed via the Win Odds (WO) method. Method: This post-hoc analysis included patients from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) glycemia trial. We employed the win ratio statistical method to estimate the treatment effects on HCE, defined as a ranked composite of all-cause mortality, kidney failure, sustained estimated glomerular filtration rate (eGFR) declines of 57, 50, and 40% from baseline, persistent eGFR < 15 mL/min/1.73 m Results: Among the 9,848 participants, sustained 40% eGFR decline was the most frequent renal event in the hierarchical composite. Intensive glucose control was not associated with a significant difference in the HCE compared to standard therapy (WO = 1.03, 95% CI: 0.99-1.07). This finding was consistent with results from Cox regression (HR = 1.05, 95% CI: 0.97-1.13) and across individual components of the composite endpoint. Conclusion: In individuals with T2DM at high risk for cardiovascular disease, intensive glycemic control does not demonstrate a significantly detrimental effect on hierarchical composite kidney outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.